

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 15, 2021**

**QUANTUM-SI INCORPORATED**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-39486**  
(Commission  
File Number)

**85-1388175**  
(IRS Employer  
Identification No.)

**530 Old Whitfield Street  
Guilford, Connecticut**  
(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: **(203) 458-7100**

**HighCape Capital Acquisition Corp.**  
**452 Fifth Avenue, 21<sup>st</sup> Floor**  
**New York, New York 10018**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A common stock, par value \$0.0001 per share	QSI	The Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of \$11.50 per share	QSIAW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure.**

From time to time, Quantum-Si Incorporated (the “Company”) presents and/or distributes slides and presentations to the investment community to provide updates and summaries of its business. On June 15, 2021, the Company updated its corporate presentation, which is available on the “Investors” section of the Company’s website at <https://ir.quantum-si.com>. This presentation is also furnished as Exhibit 99.1 to this Current Report on Form 8-K.

*The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.*

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

**Exhibit  
No.**

**Description**

---

[99.1](#)

[Corporate Presentation of Quantum-Si Incorporated dated June 15, 2021.](#)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**QUANTUM-SI INCORPORATED**

By: /s/ John Stark

Name: John Stark

Title: Chief Executive Officer

Date: June 15, 2021

---



# Quantum-Si Investor Presentation

JOHN STARK, CEO | INVESTOR UPDATE

JUNE 2021

## Forward-Looking Statements


This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results of Quantum-Si Incorporated (the “Company”) may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance, development of products and services, potential regulatory approvals, the size and potential growth of current or future markets for the Company’s future products and services, or the Company’s plans, expectations or future operations, financial position, revenues, costs or expenses. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s shares of Class A common stock on The Nasdaq Stock Market; the ability to recognize the anticipated benefits of the Company’s recently-completed business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the Company’s ability to raise financing in the future; the success, cost and timing of the Company’s product development activities; the potential attributes and benefits of the Company’s products and services; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is developing; the size and growth potential of the markets for the Company’s future products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services following anticipated commercial launch; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in the proxy statement/prospectus relating to the business combination, including those under “Risk Factors” therein, and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

---






What if we could understand how disease is progressing in real-time and provide immediate guidance on personalized treatment?






# The Next Transformation Anticipated in Life Sciences: Single Molecule Protein Sequencing




# Why is understanding the Proteome transformative?

Proteins represents the clinical end point and building blocks of life



What is there?



How much is there?



How has it been changed?

## Current State of Treatment

90% of Approved Drugs Target a Protein<sup>1</sup>

## Novel Therapies

85% of proteome undrugged<sup>2</sup>

## Patient Care

>100M Immunoassay Test/Year<sup>3</sup>

<sup>1</sup> The Human Proteome Tissue Atlas – Druggable Proteome, 2015, The Human Protein Atlas Project

<sup>2</sup> A Quest to Drug the Undruggable, June, Chemical & Engineering News, Volume 96, Issue 26, 2018

<sup>3</sup> "NPS Focus", Rainbow makers, Royal Society of Chemistry (RSC), 2003, retrieved 29 December 2012



# End-to-End Protein Analysis Platform



Sample Prep

Carbon

Universal sample preparation for both protein and DNA.



Sequencing

Platinum

Single Molecule Analysis



Analysis

Cloud

Secure data storage and analysis workflows.



# Potential Digital Disruption and Expansion of a **\$44B Market**

Quantitative Proteomics

**\$31B** (2020) **3% CAGR**

Pharmaceutical and  
diagnostic  
development

**>20,000**

Proteomics instrument  
Installations

Sequencing

**\$5B** (2020) **8% CAGR**

Basic Research,  
Discovery and  
Emerging Clinical  
Application

**>16,000**

Bench Top DNA Digital  
Sequencing Systems

Clinical Testing

**\$8B** (2020) **15% CAGR**

Precision Medicine  
Targeted Therapies

**>132M**

Molecular tests performed  
each year in U.S

Data collected from SDI Global Report 2020 and Cowen Equity Research Life Science tools Kit 12th Edition.

# Novel Biological Understanding: Next Frontier of Assessing Recurrence and Treatment


## Post-translational Modifications

Our technology detects post-translational modifications like any other amino acid. We can currently recognize phosphorylated tyrosine on chip and are working on other PTMs.


## Pathways Activation

Tyrosine phosphorylation is a marker for pathway activation, e.g. how cells responds to drugs, infection.


Tyrosine



Phosphorylated Tyrosine



A



Estimated \$10B/Year Therapy Market Opportunity  
EGFR/HER2 (Breast and Lung)

# And finally delivering on what we believe the market demands

	Mass Spec	Digital DNA Sequencing	Single Molecule DNA Sequencing	Quantum-Si
Quantitative Analysis (Protein)	✓	----	----	✓
Quantitative Analysis (DNA)	----	✓	✓	✓
Benchtop System	----	✓	----	✓
Single Molecule	----	----	✓	✓



# Well Positioned to be a Leader in the Proteomics Revolution




Sample Preparation	✓	----	----	✓
Single Molecule	----	----	✓	✓
Analysis Platform*	----	----	✓	✓
Protein Identification	----	✓	✓	✓
Protein Quantitation	----	✓	----	✓
Analysis Output	----	----	✓	✓



# Pathway for Growth and Customer Adoption

## Status:

- ✓ Optimized Workflow and Data Analysis
- ✓ Scaled Production/Supply Chain
- ✓ First Two Systems Shipped Q1, 2021



2021

2025

QUANTUM SI

INVESTOR UPDATE

PROPRIETARY & CONFIDENTIAL


12



# Valuation Potential

## Illumina

Revenues  
\$ Millions




\$65BN+ Market Cap Today<sup>1</sup>

- 2006 launch
- Leveraged foothold in the genomics market

## 10X Genomics

Revenues  
\$ Millions



\$21BN+ Market Cap Today<sup>1</sup>

- 2016 launch
- Leveraged the Human Cell Atlas program and Illumina footprint

## Seer

Pre-commercial

\$1.9BN+ Market Cap Today<sup>1</sup>

- 2020 IPO
- 2022 anticipated commercial launch<sup>2</sup>

<sup>1</sup>As of market close on Friday, January 29 2021

<sup>2</sup><https://www.genomeweb.com/proteomics-protein-research/seer-using-310m-fundraise-prep-broad-commercial-launch-proteomic>



# Meet the Team



**JONATHAN ROTHBERG**  
*Executive Chairman*



**JOHN STARK**  
*Chief Executive Officer*



**MIKE MCKENNA**  
*Chief Operations Officer*



**CHRISTIAN LAPOINTE**  
*General Counsel*



**CLAUDIA DRAYTON**  
*Chief Financial Officer*



**MATT DYER**  
*Chief Business Officer*



**GERARD SCHMID**  
*Head of Chip Manufacturing*



**TODD REARICK**  
*Chief Technology Officer*



**KIEREN PATEL**  
*Head of Product and Marketing*



**BRIAN REED**  
*Head of Research*



**FAISAL AHMAD**  
*Head of Optical Devices*



**MEL DAVEY**  
*Head of Software*



**MIKE FERRIGNO**  
*Head of Hardware*



**LINDSAY THOMPSON**  
*Head of People*

>120 Employees



## Pioneering Next Generation Single Molecule Sequencing



QuantumSi

- Commercializing single-molecule protein sequencing platform scaled by a first of its kind semiconductor chip with over 550<sup>1</sup> issued and pending patents
- Positioned for massive market expansion and to digitize a \$44B<sup>2</sup> legacy proteomics research and diagnostic markets
- Leveraging decades of advancement in digital DNA sequencing, QSi is poised to become the market leader in single molecule protein sequencing

<sup>1</sup>Over 100 issued patents and 450 pending patent applications across 125 patent families

<sup>2</sup>Data collected from SDI Global Report 2020 and Cowen Equity Research Life Science tools Kit 12th Edition.